Rucaparib meets primary endpoint in ARIEL 4 phase 3 trial in patients with later-line ovarian cancer with a BRCA mutation

Study (n=325; ≥2 prior lines chemotherapy) reports rucaparib linked to significantly improved investigator-assessed progression-free survival vs. chemotherapy (median 7.4 vs. 5.7 months, HR 0.639; p=0.0010). Completion of ARIEL4 is a post-marketing commitment in U.S. and EU.

Biospace Inc.